Journal of neuroendocrinology

Glucagon-like peptide-1 drugs and their impact on prolactin hormone levels in a controlled clinical trial

Updated

Abstract

PRL levels changed by -31.1 mU/L on dulaglutide and +44.6 mU/L on placebo over 4 weeks.

  • Dulaglutide treatment resulted in a reduction of PRL concentrations compared to placebo.
  • More than half of participants experienced decreases in both PRL and appetite scores on dulaglutide.
  • Reductions in PRL levels on dulaglutide correlated weakly with weight loss.
  • No association was found between PRL levels and sexual desire during the trial.
  • Further investigation is warranted to explore the neuroendocrine effects of GLP-1 receptor activation.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free